Skip to main content
. Author manuscript; available in PMC: 2023 Aug 5.
Published in final edited form as: Vaccine. 2022 Jun 27;40(33):4764–4771. doi: 10.1016/j.vaccine.2022.06.059

Figure 1. Serum concentrations of antibodies to pneumococcal serotypes among 134 infants immunized with PCV-13 in Botswana by infant HIV exposure status.

Figure 1.

Box plots depict natural log-transformed serum antibody concentrations (μg/mL) to each of the 13 vaccine serotypes in HIV-exposed, uninfected (HEU) and HIV-unexposed, uninfected (HUU) infants receiving PCV-13 in a 3+0 schedule with doses at 2, 3, and 4 months of age. Each point represents the concentration in a single sample; boxes represent the 25th to 75th percentile with median values shown as a line. The dark purple points and boxes correspond to antibody concentrations of HEU infants and the light purple points and boxes correspond to antibody concentrations of HUU infants. Statistical comparisons of serum antibody concentrations by HIV exposure status were performed using linear regression adjusting for infant birth weight and maternal age with significant differences indicated by asterisks. M0, birth (0 months); M5, 5 months of age; M12, 12 months of age